Recent insights have reclassified certain investigational anti-cancer agents, such as indisulam and tasisulam, as RBM39 molecular glue degraders targeting pre-mRNA splicing factors implicated in various cancers. Building on this understanding, next-generation degraders from SEED and Recursion demonstrate enhanced potency and selectivity. This advancement underscores the growing significance of molecular glue technology in oncology drug development, offering promising avenues for treating ER-positive breast and ovarian tumors.